Early intervention can significantly improve the development and prognosis of T1DM, and effective biomarkers are great significance for the early prediction and diagnosis of T1DM. As a diabetes focused solution provider, Ace Metabolism has established a multi-functional CRO platform service. We can provide researchers engaged in biomarker development of diabetes with more efficient function analysis.

Biomarkers of T1DM

Some biomarkers can be used for the diagnosis and the prediction of disease risk of T1DM, including genetic markers, pancreatic islets β-cell autoantibodies, T cell biomarkers and emerging biomarkers.

• Genetic Marker
  The genetic risk assessment of T1DM is mainly based on human leukocyte antigen (HLA) typing, and the most critical gene is HLA class II antigen gene. The HLA-DR 3, HLA-DR 4 and HLA-DQ 8 genotypes can be used to predict the risk of T1DM.

• Pancreatic Islets β-cell Autoantibodies
  Pancreatic islets β-cell autoantibodies, do not directly lead to T1DM, but they have become one of the most commonly used classical biomarkers for predicting T1DM.

• T Cell Biomarkers
  Some components of innate and adaptive immune systems are related to β-cell destruction, but T cells are the main mediators. T cell biomarkers can be divided into two categories: antigen-specific and non-antigen-specific.

Learn more: diabetes biomarker development service